Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Journal for ImmunoTherapy of Cancer

Figure 1

From: A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

Figure 1

Serum CA125 in the four confirmed (202, 208, 219, 228) and one unconfirmed (220) responding or stabilizing patients including the period of pretrial evaluation. Cvac treatments began on day 1 and are indicated as (▲). The day of withdrawal from the trial is indicated as (), except for patients 219 and 228 where data are truncated at 12 months.

Back to article page